PFM046

PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRα and LXRβ with IC50 of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models[1].

Product Specifications

CAS Number

[3053859-57-4]

UNSPSC

12352005

Target

Fatty Acid Synthase (FASN) ; LXR; Stearoyl-CoA Desaturase (SCD)

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer

Smiles

C[C@@]12[C@](CC[C@]2([H])[C@H](C)[C@H](CC3=CC=CC=C3)O)([H])[C@]4([H])CC=C5C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC1

Molecular Formula

C29H42O2

Molecular Weight

422.64

References & Citations

[1]Pontini L, et al., Discovery of 22 (S) -23-phenyl-24-norchol-5-en-3β,22-diol (PFM046) as the first-in-class, steroidal, non-sulfated Liver X Receptor antagonist with anticancer activity. Eur J Med Chem. 2025 Feb 5;283:117136.